Conclusion
NSCLC
DISEASE PROGRESSION, NSCLC
DS‐1205c was generally safe and well tolerated at all dose levels, but the safety profile of ≤800 mg BID was more favorable than 1200 mg BID. The recommended dose for dose‐expansion cohorts of DS‐1205c in combination therapy with gefitinib was 800 mg BID.Schematic showing the design of this first‐in‐human multicenter, open‐label Phase 1 study of DS‐1205c in combination with gefitinib in subjects with metastatic or unresectable EGFR‐mutant NSCLC and disease progression during treatment with one or more EGFR‐TKIs (gefitinib, erlotinib, afatinib, dacomitinib, or osimertinib).
